{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:57:31Z","timestamp":1792785451486,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Vaccine Research Center","id":[{"id":"https:\/\/ror.org\/02fve6a73","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.coi.2015.06.006","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T17:19:52Z","timestamp":1438795192000},"page":"131-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine"],"prefix":"10.1016","volume":"35","author":[{"given":"Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2015.06.006_bib0175","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2014.10.006","article-title":"Camouflage and misdirection: the full-on assault of ebola virus disease","volume":"159","author":"Misasi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.coi.2015.06.006_bib0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm0198-037","article-title":"Immunization for Ebola virus infection","volume":"4","author":"Xu","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2015.06.006_bib0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1006\/viro.1998.9176","article-title":"DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge","volume":"246","author":"Vanderzanden","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.coi.2015.06.006_bib0190","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.4049\/jimmunol.174.7.4198","article-title":"CD8-mediated protection against Ebola virus infection is perforin dependent","volume":"174","author":"Gupta","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2015.06.006_bib0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2015.06.006_bib0200","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/mp4001316","article-title":"Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine","volume":"10","author":"Choi","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.coi.2015.06.006_bib0205","doi-asserted-by":"crossref","first-page":"9378","DOI":"10.1073\/pnas.94.17.9378","article-title":"Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination","volume":"94","author":"Letvin","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2015.06.006_bib0210","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.coi.2015.06.006_bib0215","doi-asserted-by":"crossref","first-page":"e1000904","DOI":"10.1371\/journal.ppat.1000904","article-title":"Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species","volume":"6","author":"Hensley","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2015.06.006_bib0220","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nature01876","article-title":"Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates","volume":"424","author":"Sullivan","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.coi.2015.06.006_bib0225","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"10.1016\/j.coi.2015.06.006_bib0230","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","article-title":"Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge","volume":"196","author":"Warfield","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2015.06.006_bib0235","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.06.006_bib0240","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1128\/JVI.02864-12","article-title":"Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates","volume":"87","author":"Richardson","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.06.006_bib0245","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.aaa4919","article-title":"Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates","volume":"348","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.coi.2015.06.006_bib0250","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.coi.2015.06.006_bib0255","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coi.2015.06.006_bib0260","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2015.06.006_bib0265","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2015.06.006_bib0270","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.06.006_bib0275","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2003-12-4341","article-title":"HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha","volume":"104","author":"Lichterfeld","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.coi.2015.06.006_bib0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2015.06.006_sbref0285","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2015.06.006_bib0290","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ420","article-title":"Supportive care of the first two Ebola virus disease patients at the Monrovia Medical Unit","author":"Wong","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2015.06.006_bib0295","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M15-0530","article-title":"Characteristics and clinical management of a cluster of 3 patients with ebola virus disease, including the first domestically acquired cases in the United States","volume":"163","author":"Liddell","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coi.2015.06.006_sbref0300","article-title":"Chimpanzee adenovirus vector Ebola vaccine\u2014preliminary report","author":"Ledgerwood","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2015.06.006_bib0305","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1473-3099(15)00027-4","article-title":"Approaches to demonstration of Ebola virus vaccine efficacy","volume":"15","author":"Krause","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2015.06.006_sbref0310","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2015.06.006_bib0315","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial","volume":"211","author":"Sarwar","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2015.06.006_bib0320","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine\u2014preliminary report","author":"Rampling","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2015.06.006_bib0325","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1473-3099(15)70139-8","article-title":"Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis","volume":"15","author":"Bellan","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2015.06.006_bib0330","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(15)70106-4","article-title":"Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?","volume":"15","author":"Lanini","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2015.06.006_bib0335","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-immunol-031210-101255","article-title":"Trafficking of B cell antigen in lymph nodes","volume":"29","author":"Gonzalez","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coi.2015.06.006_sbref0340","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J Clin Invest"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791515000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791515000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:31:57Z","timestamp":1760603517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791515000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":34,"alternative-id":["S0952791515000874"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2015.06.006","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2015.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}